1.5期翻修治疗假体周围关节感染的系统综述
本系统综述纳入13项研究共924例患者(704膝、228髋),分析其中556例(428膝、136髋)接受1.5期翻修者的结局,平均随访3.8±1.1年,平均成功率为86.8%,感染所致平均失败率为12.6%;与2期翻修相比,感染无生存率相似或更高,且短期随访中90天疼痛评分、术后并发症和费用有降低趋势。
要点
- 1.5期翻修平均随访3.8±1.1年,平均成功率为86.8%,感染所致平均失败率为12.6%。
- 一项研究中1.5期翻修组感染无生存率高于2期翻修组(94% vs 83%,P = 0.048),其余5项研究无显著差异。
- 1.5期翻修组在短期随访(<5年)中90天疼痛评分、术后并发症和费用有降低趋势。
核心结论
- 1.5期翻修是假体周围关节感染可行且具成本效益的治疗选择。
- 与2期翻修相比,1.5期翻修的感染无生存率相似或更高。
- 在短期随访(定义为小于5年)中,1.5期翻修与更低的90天疼痛评分、术后并发症和费用相关。
- 为更好描述该术式,作者建议将其更名为半永久性抗生素洗脱翻修术。
研究设计与样本
- 系统综述,遵循PRISMA 2020指南,由两名评价者通过PubMed、Scopus和Embase数据库检索。
- 最终纳入13项研究,共924例患者(704膝和228髋);其中556例患者(428膝和136髋)接受1.5期翻修并纳入分析。
- 采用标准化模板提取人口学信息(年龄、体质指数[BMI])、成功/失败率、平均随访时间(年)及与2期翻修相比的感染无生存率。
- 1.5期翻修患者平均年龄65岁(范围60至78),平均体质指数31(范围23.7至34.4)。
- 证据等级为IV级。
主要发现
- 在平均随访3.8±1.1年时,平均成功率为86.8%。
- 感染所致平均失败率为12.6%。
- 在一项研究中,1.5期翻修队列的感染无生存率高于2期翻修队列(94% vs 83%,P = 0.048)。
- 其余五项评估感染无生存率的研究发现无显著差异。
- 1.5期翻修队列在90天疼痛评分、术后并发症和费用方面有降低趋势。
临床怎么用
- 作者认为1.5期翻修是假体周围关节感染可行且具成本效益的治疗选择。
- 作者认为与2期翻修相比,1.5期翻修的感染无生存率相似或更高。
- 作者认为在短期随访(小于5年)中,1.5期翻修与更低的90天疼痛评分、术后并发症和费用相关。
- 作者建议将该术式更名为半永久性抗生素洗脱翻修术以更好描述该操作。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although the two-stage exchange is the gold standard for the treatment of periprosthetic joint infection (PJI) in the United States, there is recent data to suggest that the utilization of a well-functioning destination spacer, also known as a "functional" or "1.5-stage revision," can be a viable treatment option in patients who have a PJI. The purpose of this systematic review was to evaluate the outcomes of patients undergoing a 1.5-stage revision for PJI and compare outcomes to a two-stage revision. METHODS: A systematic review was performed through PubMed, Scopus, and Embase databases. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines were followed utilizing two reviewers. Following exclusions, 13 studies (n = 924 patients, 704 knees and 228 hips) were identified and included. A standardized template was utilized to capture demographic information (age, body mass index [BMI]), success/failure rate, mean follow-up time (years), and infection-free survivorship compared to two-stage revision. There were 556 patients (428 knees and 136 hips) who had 1.5-stage revisions included in the analyses. The mean age and body mass index were 65 years (range, 60 to 78) and 31 (range, 23.7 to 34.4), respectively. RESULTS: At a mean follow-up time of 3.8 ± 1.1 years, the mean success rate was found to be 86.8%. The mean failure rate due to infection was 12.6%. In one study, infection-free survivorship was greater in the 1.5-stage revision cohort when compared to the two-stage revision cohort (94 versus 83%, P = 0.048). The remaining five studies that evaluated infection-free survivorship found no significant difference. However, there was a trend toward decreased the 90-day pain scores, postoperative complications, and cost in the 1.5-stage cohort. CONCLUSIONS: Our systematic review demonstrated that a 1.5-stage revision is a viable and cost-effective treatment option for patients who have PJI. Infection-free survivorship was similar or greater when comparing a 1.5-stage revision to a two-stage revision. A 1.5-revision was associated with lower 90-day pain scores, postoperative complications, and decreased cost when compared to the two-stage revision in short-term follow-up, defined as less than five years. To better describe the procedure, we propose the name change to semipermanent eluting antibiotic revision procedure. LEVEL OF EVIDENCE: IV.
引用
- Khnanisho M, Horne C, Deckey DG, et al. 1.5-Stage Revision for the Treatment of Periprosthetic Joint Infection: A Systematic Review. J Arthroplasty. 2025. PMID: 40015380. doi:10.1016/j.arth.2025.02.057
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。